These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 3258546)

  • 1. Pharmacokinetics of tumor-reactive immunotoxins in tumor-bearing mice: effect of antibody valency and deglycosylation of the ricin A chain on clearance and tumor localization.
    Fulton RJ; Tucker TF; Vitetta ES; Uhr JW
    Cancer Res; 1988 May; 48(9):2618-25. PubMed ID: 3258546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ; Uhr JW; Vitetta ES
    Cancer Res; 1988 May; 48(9):2626-31. PubMed ID: 3258547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of chemical deglycosylation of ricin A chain on the in vivo fate and cytotoxic activity of an immunotoxin composed of ricin A chain and anti-Thy 1.1 antibody.
    Blakey DC; Watson GJ; Knowles PP; Thorpe PE
    Cancer Res; 1987 Feb; 47(4):947-52. PubMed ID: 3492271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
    Pietersz GA; Kanellos J; McKenzie IF
    Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
    Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
    Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
    Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of ricin A chain immunotoxins prepared from intact antibodies and Fab' fragments on solid human Hodgkin's disease tumors in mice.
    Engert A; Martin G; Pfreundschuh M; Amlot P; Hsu SM; Diehl V; Thorpe P
    Cancer Res; 1990 May; 50(10):2929-35. PubMed ID: 1692251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parameters affecting tumor-specific delivery of anti-CD5 antibody-ricin A chain immunotoxins in vivo.
    Rostaing-Capaillon O; Casellas P
    Cancer Res; 1990 May; 50(10):2909-16. PubMed ID: 1692250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain- and ricin B chain-containing immunotoxins.
    Fulton RJ; Uhr JW; Vitetta ES
    J Immunol; 1986 Apr; 136(8):3103-9. PubMed ID: 3958490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
    Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical assessments of 90Y-labeled C110 anti-carcinoembryonic antigen immunotoxin: a therapeutic immunoconjugate for human colon cancer.
    Ito T; Qiu H; Collins JA; Brill AB; Johnson DK; Griffin TW
    Cancer Res; 1991 Jan; 51(1):255-60. PubMed ID: 1988087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA; Richardson J; Tucker T; Jones D; Uhr JW; Vitetta ES
    Cancer Res; 1991 Nov; 51(21):5876-80. PubMed ID: 1933855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography.
    Sung C; Dedrick RL; Hall WA; Johnson PA; Youle RJ
    Cancer Res; 1993 May; 53(9):2092-9. PubMed ID: 8481911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ricin A chain-containing immunotoxins directed against the CD30 antigen as potential reagents for the treatment of Hodgkin's disease.
    Engert A; Burrows F; Jung W; Tazzari PL; Stein H; Pfreundschuh M; Diehl V; Thorpe P
    Cancer Res; 1990 Jan; 50(1):84-8. PubMed ID: 2152774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
    Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the helper function of murine T cells with Fab'-anti-L3T4 ricin A chain immunotoxin.
    Street NE; Fulton RJ; Sanders VM; Vitetta ES
    J Immunol; 1987 Sep; 139(5):1734-8. PubMed ID: 2957434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.
    Yokota T; Milenic DE; Whitlow M; Wood JF; Hubert SL; Schlom J
    Cancer Res; 1993 Aug; 53(16):3776-83. PubMed ID: 8339291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
    Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
    Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the cytotoxic potency of T101 Fab, F(ab')2 and whole IgG immunotoxins.
    Derocq JM; Casellas P; Laurent G; Ravel S; Vidal H; Jansen F
    J Immunol; 1988 Oct; 141(8):2837-43. PubMed ID: 3262669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.
    Ghetie MA; Uhr JW; Vitetta ES
    Cancer Res; 1991 Mar; 51(5):1482-7. PubMed ID: 1705175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.